Corhythm is an early stage company developing a novel therapy for the treatment of atrial fibrillation. More than three million Americans suffer from atrial fibrillation or a rapid, irregular heart rhythm. Atrial fibrillation is the most common cardiac arrhythmia and the leading cause of stroke and heart failure. While current therapies exist, none represent an ideal treatment due to limited efficacy and undesirable side effects.
Corhythm has developed a drug-device combination therapy: an implantable pharmacologic atrial defibrillator. The therapy device detects the onset of AF, and delivers a powerful pharmacologic agent to the heart in small quantities through an implanted catheter through the implanted device. Local drug delivery eliminates systemic side effects, and silences the arrhythmia. The patient does not experience any pain, as is the case with electrical cadioversion.
Corhythm’s approach is unlike any other treatment available today, and we believe there is potential for much higher efficacy rates without the undesirable side effects experienced with current therapies. The company is actively developing the technology and is conducting pre-clinical studies.